Abstract #2520

MRI/MRS monitoring of anti-tumor treatments in an in vivo orthotopic model of a mammary tumor cell line expressing the d16HER2 variant

Gianmauro Palombelli¹, Egidio Iorio¹, Giulia Carpinelli², Martina Borghi³, Francesco Lozupone⁴, Tommaso Azzarito⁴, Manuela Iezzi⁵, Ada Koschorke⁶, Elda Tagliabue⁶, Serenella Pupa⁶, and Rossella Canese¹

¹Cell Biology and Neurosciences, Istituto Superiore di Sanita', Roma, Italy, ²Cell Biology and Neusciences, Istituto Superiore di Sanita', Rome, Italy, ³Infectious, Parasitic and Immune-mediate Diseases, Istituto Superiore di Sanita', Roma, Italy, ⁴Drug Research and Evaluation, Istituto Superiore di Sanita', Roma, Italy, ⁵Medicine and Aging Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy, ⁶Experimental Oncology and Molecular Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

The HER2 splice variant lacking exon-16 (d16HER2) has been detected in human breast carcinomas.It has been shown in proper transgenic mouse models that d16HER2 variant leads to an increased transforming potency compared to the wild-type (wt) HER2 receptor. In this work, a murine mammary carcinoma cell line transgenically expressing the human d16HER2 variant (MI6 cells)-was implanted in the mammary fat pad of parental FVB mice which were treated with lapatinib or phenethyl isothiocyanate (PEITC), respectively targeting HER2 receptor and breast cancer initiating cells , and analyzed by in vivo DWI and quantitative MRS analyses.

This abstract and the presentation materials are available to members only; a login is required.

Join Here